Boehringer Ingelheim Selects Genedata Biologics as Antibody Discovery Workflow Platform
News Feb 19, 2015
Genedata has announced that Boehringer Ingelheim has chosen Genedata Biologics™ as their global biologics R&D workflow and data management platform. The Genedata Biologics platform will support multiple Boehringer Ingelheim R&D groups in the US and Europe, including Lead Identification and Screening, Lead Optimization and Engineering, and Protein Production groups across Boehringer Ingelheim's New Biological Entities (NBEs) centers.
"Our Biotherapeutics Research division required a central system to support the complex and interconnected workflows in our large-molecule discovery units," said Dr. Miguel Teodoro, Head of IT Research at Boehringer Ingelheim. "We undertook a thorough selection process to find the best antibody workflow platform and Genedata Biologics was the obvious choice. We believe Genedata Biologics will help us to accelerate our antibody discovery programs as we develop the next generation of biologics drugs."
Genedata Biologics streamlines biopharma discovery operations by integrating workflows and data from diverse research processes and antibody discovery platforms, such as phage and yeast display, hybridomas, and B-cells, as well as downstream expression, purification, and analytics.
Genedata Biologics reduces data capture and reporting time by 50% and significantly improves candidate quality through standardized and automated data integrity analysis. In addition, the system greatly increases experimental throughput by directly interfacing with laboratory automation instruments.
"We are excited that Boehringer Ingelheim, a global leader in biopharmaceuticals, has chosen Genedata Biologics for data management and processing to support their New Biological Entities units," said Dr. Othmar Pfannes, CEO of Genedata. "This latest addition to the rapidly growing list of leading biopharmas partnering with Genedata proves again the value of our platform, which speeds up the discovery, optimization, and development of novel biopharmaceuticals. We are committed to continuing to expand the platform to meet the rapidly developing new requirements in this exciting field."